title: Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma.
abstract: Elderly patients with non-Hodgkin lymphoma (NHL) have a poor prognosis. Owing to treatment-related toxicities, there is no standard chemotherapy for the elderly patients, especially those aged 70 years or older. In this study, we retrospectively evaluated the efficacy and toxicity of reduced-dose (two-thirds) R-CHOP chemotherapy as an initial chemotherapy for 45 patients aged 70 years or older with B-cell NHL. The WHO classification of NHL included diffuse large B-cell lymphoma (DLBCL) (31), mantle cell lymphoma (5), follicular lymphoma (4), extranodal marginal zone lymphoma (1), Burkitt lymphoma (1), and B-cell lymphoma whose further types were unclassified (3). The incidences of grade 4 neutropenia and febrile neutropenia (FN) were 51.1 and 15.6%, respectively. Efficacy was evaluated in patients with DLBCL. The overall and complete response (CR) rates were 96.7 and 90.0%, respectively. Two-year event-free survival (EFS) and overall survival (OS) were 84.4 and 89.2%, respectively. There was no treatment-related mortality. In conclusion, two-thirds R-CHOP chemotherapy is a promising treatment for elderly patients with B-cell NHL in terms of its efficacy and toxicity.
authors.forename: Misato
authors.initials: M
authors.lastname: Kikuchi
authors.forename: Hideki
authors.initials: H
authors.lastname: Nakasone
authors.forename: Yu
authors.initials: Y
authors.lastname: Akahoshi
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Nakano
authors.forename: Tomotaka
authors.initials: T
authors.lastname: Ugai
authors.forename: Hidenori
authors.initials: H
authors.lastname: Wada
authors.forename: Ryoko
authors.initials: R
authors.lastname: Yamasaki
authors.forename: Kana
authors.initials: K
authors.lastname: Sakamoto
authors.forename: Koji
authors.initials: K
authors.lastname: Kawamura
authors.forename: Yuko
authors.initials: Y
authors.lastname: Ishihara
authors.forename: Miki
authors.initials: M
authors.lastname: Sato
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ashizawa
authors.forename: Kiriko
authors.initials: K
authors.lastname: Terasako-Saito
authors.forename: Shun-ichi
authors.initials: S
authors.lastname: Kimura
authors.forename: Rie
authors.initials: R
authors.lastname: Yamazaki
authors.forename: Shinichi
authors.initials: S
authors.lastname: Kako
authors.forename: Junya
authors.initials: J
authors.lastname: Kanda
authors.forename: Junji
authors.initials: J
authors.lastname: Nishida
authors.forename: Naohiro
authors.initials: N
authors.lastname: Sekiguchi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Noto
authors.forename: Michiko
authors.initials: M
authors.lastname: Kida
authors.forename: Akira
authors.initials: A
authors.lastname: Hangaishi
authors.forename: Kensuke
authors.initials: K
authors.lastname: Usuki
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Kanda
mesh_terms: D000046:Academic Medical Centers; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D064146:Chemotherapy-Induced Febrile Neutropenia / Q000453:epidemiology / Q000503:physiopathology; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced / Q000453:epidemiology / Q000503:physiopathology; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011379:Prognosis; D012189:Retrospective Studies; D012306:Risk; D000069283:Rituximab; D012720:Severity of Illness Index; D016019:Survival Analysis; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: Diffuse large B-cell lymphoma,; Elderly patients,; Neutropenia,; Non-Hodgkin lymphoma,; R-CHOP; Relative dose intensity,; Rituximab,